#cancer therapy #Denmark #Copenhagen #Adcendo #ADCE-D01

Adcendo ApS to Showcase Key Clinical Data

Adcendo ApS, a prominent biotechnology firm, is set to reveal significant clinical data related to its innovative antibody-drug conjugate (ADC) known as ADCE-D01. The presentation is scheduled for the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, commencing on November 18, 2026, in the vibrant city of Barcelona, Spain.

Highlighting the ADCElerate1 Trial

The spotlight will be on the early results from the Phase 1 clinical trial, ADCElerate1, which is particularly focused on patients diagnosed with advanced soft tissue sarcoma. This targeted therapy represents a first-in-class approach, targeting the unique biomarker, uPARAP, which plays a critical role in cancer metastasis and progression. The presentation will be conducted by Dr. Patrick Schöffski from University Hospitals Leuven and KU Leuven, Belgium, during a plenary session dedicated to clinical trials.

Presentation Details

• - Title: A novel antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein in previously treated patients with advanced soft tissue sarcoma: emerging clinical results from the phase 1 ADCElerate1 study (NCT06797999)
• - Presenter: Dr. Patrick Schöffski
• - Session: Plenary Session 3 – Proffered Papers Clinical Trials
• - Abstract number: 4LBA
• - Date and Time: Thursday, November 19, 2026, at 10:00 a.m. CET / 4:00 a.m. ET

About Adcendo ApS

Adcendo was founded with the mission to pioneer innovative cancer therapies, specifically focusing on developing differentiated ADCs. With its headquarters in Copenhagen, Denmark, and operational presence in Boston, Massachusetts, the company is driven by a robust team of seasoned executives who have a proven history of successfully advancing ADCs through development to market approval.

The company's approach emphasizes a balance between efficacy and tolerability, employing a disease- and target-driven methodology in ADC development. Currently, Adcendo is working on three notable ADC programs targeting high unmet medical needs. These programs include therapies for soft tissue sarcoma, squamous cell cancers, pancreatic ductal adenocarcinoma, and various other solid tumors.

As Adcendo prepares to present its preliminary findings, the biotechnology community anticipates a significant contribution to the ongoing combat against soft tissue sarcoma, a type of cancer that typically presents challenges regarding treatment and management. The ADCE-D01 trial results could represent a breakthrough not only for patients suffering from advanced sarcomas but also for the broader oncology field, which continually seeks innovative therapeutic strategies.

For those interested in the details of Adcendo’s research initiatives or to learn more about their promising pipeline, further information can be found on their official website or through their LinkedIn page.

The upcoming symposium promises to be a grand platform for discussing groundbreaking cancer therapies, and Adcendo's presentation is surely one of the highlights that will capture the attention of medical professionals and researchers alike. Stay tuned for updates and insights into their robust ADC portfolio following the event.